← All trials
NCT00354926
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 1, 2006
- Primary completion
- Jan 1, 2009
- Completion date
- Jan 1, 2009
- First posted
- —
- Last posted
- —
- Enrollment
- 67
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- Applied Molecular EvolutionLead sponsor
- University of IowaOverall official - principal investigator
- Nevada Cancer InstituteOverall official - principal investigator
- University of California, Los AngelesOverall official - principal investigator
- Stanford UniversityOverall official - principal investigator
- University of PittsburghOverall official - principal investigator
- Rush UniversityOverall official - principal investigator
- SCRI Development InnovationsOverall official - principal investigator
- University of RochesterOverall official - principal investigator
- University of VirginiaOverall official - principal investigator
- University of AlabamaOverall official - principal investigator
- Temple UniversityOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.